Data Management Featured Articles
-
IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For February 2016
3/1/2016
Below are my top three articles downloaded on Clinical Leader for the month of February 2016. In case you missed them, please take this opportunity to see what everyone else was learning about protocol design and EMA recommendations surrounding the clinical tragedy in France, and biopharma trends that will impact clinical trials in 2016.
-
Data Security In Mobile Health Apps: Does Perception Match Reality?
2/29/2016
The use of mobile apps has exploded in recent years. One report, put out by mobile analytics firm Flurry, shows app usage grew by 76 percent in just 2014 alone. Health and fitness apps were one of the leading categories, showing growth of 89 percent. With the number of apps in the Google Play store exceeding 1.6 million, and the number of app downloads projected to hit 268,692 million in 2017, the use of mobile technologies will not slow anytime soon.
-
Can Sharing Clinical Notes Increase Patient Engagement And Retention?
2/25/2016
If patients are more engaged with a study, and take more of an ownership role in their health and data, it’s believed they will become more attached to the study and the treatment. Some pharma companies are even looking into the possibility of patients being able to review and delete their own data. But what about notes that are recorded by a physician during a patient’s visit to a clinic? Should that information also be shared with patients?
-
ClinicalTrials.gov: Progress Made, But One-Third Of Results Still Missing
2/24/2016
<p>ClinicalTrials.gov was created to inform the public of the results of clinical trials. Since the database went live in 2008, it has accumulated data on 200,000 trials in more than 170 countries. Compliance with established requirements is improving, but according to NIH data recently shared by Sen. Charles Grassley of Iowa, more than a third of applicable study results are still missing.</p>
-
Report: Pharma Is Most Resistant To Mobile Technology Use In Clinical Trials
2/17/2016
There are several technologies that promise to improve the ease and efficiency of conducting clinical trials in the future. The one that seems to hold the most potential for also easing the burden on patients, and helping sponsors with patient recruitment and retention, is mobile health technologies. But is the adoption rate of mHealth in clinical trials increasing?
-
Clinical Outsourcing Market To See Continued Growth Through 2020
2/11/2016
A recent report from ISR, titled 2016 CRO Market Size Projections 2015-2020, paints an exciting and eventful future for the clinical trials market. This market has certainly been one of the best performing of late. In 2015, while the DJIA was down around 10 percent, clinical companies like PRA Health (up 78 percent), INC Research (up 64 percent) ICON (up 19 percent), Quintiles (up 6 percent), and PAREXEL (up 2 percent), all had great years.
-
Biopharma Trends That Will Impact The Industry In 2016
2/9/2016
The beginning of the year is always a good time to take a look ahead at the trends most likely to impact the industry in the coming months. One area that is changing quickly, and which promises to impact clinical trials in the coming years, is biopharma. I recently spoke with Jim Esinhart, CEO of Chiltern, about some of these trends, including study protocols, big data, mergers, and new technologies.
-
In Pharma Mobile Technology Makes Gains, Patient Enrollment Remains A Struggle
2/4/2016
A new report has been released by Insight Pharma Reports with some eye-opening results sure to get the attention of clinical executives. The Patient Enrollment & Recruitment Market Study performed a survey of 100 clinical trial professional staff members regarding their experiences with patient enrollment and recruitment.
-
Using The Cost Of Adverse Events To Determine Drug Safety
2/3/2016
There are limitations to the drug approval system we currently have in place that is based on clinical trials. Data disclosures are often deemed inadequate, regulatory review and approval can be a lengthy process, and many would argue there is a bias in the industry and academia against publishing negative results.
-
Patient-Reported Outcomes: Engaging Patients As Partners For Better Pharmacovigilance Practices
1/29/2016
Today, there is greater awareness surrounding the benefit and risk of pharmaceutical products, amongst health care professionals (HCPs) and consumers alike. Safety and efficacy data from clinical trials are no longer sufficient and there is a demand for more evidence including effectiveness of treatments as well as comparative effectiveness, relative to other therapies.